Novo Nordisk A/S. (NYSE:NVO) has found that its "miracle" weight loss drug used for diabetes,Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.
What Happened: A study conducted at the University of Oxford revealed that patients who used Ozempic had a 48% lower risk of dementia compared to those who used an older drug, sitagliptin. The study also showed a lower risk of cognitive deficits in comparison to patients who had taken either sitagliptin or glipizide, another older medicine, reported Bloomberg on Friday.
Patients on Ozempic also had a 28% lower risk...
Login or create a forever free account to read this news
Sign up/Log in